Showing results (31-40 of 50) with videos related to
Sort By:
Pageof 5
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trialTarik Asselah, Christophe Hézode, Roula B Qaqish, et al.Molecular Cancer Therapeutics|May 16, 2013
Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancerBrian F Clem, Julie O'Neal, Gilles Tapolsky, et al.Antimicrobial Agents and Chemotherapy|November 29, 2017
Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in JapanPreethi Krishnan, Gretja Schnell, Rakesh Tripathi, et al.Lancet (London, England)|April 4, 2015
Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trialChristophe Hézode, Tarik Asselah, K Rajender Reddy, et al.Gastroenterology|July 15, 2015
Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without CirrhosisEric Lawitz, Mihály Makara, Ulus Salih Akarca, et al.The Lancet. Gastroenterology & Hepatology|April 14, 2017
Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trialImam Waked, Gamal Shiha, Roula B Qaqish, et al.Journal of Medical Virology|August 27, 2017
Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavirGretja Schnell, Rakesh Tripathi, Preethi Krishnan, et al.Hepatology (Baltimore, Md.)|July 7, 2015
Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosisHiromitsu Kumada, Kazuaki Chayama, Lino Rodrigues, et al.Journal of Gastroenterology|November 15, 2017
Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infectionHiromitsu Kumada, Tsunamasa Watanabe, Fumitaka Suzuki, et al.Journal of Gastroenterology|October 21, 2017
Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infectionHiromitsu Kumada, Tsunamasa Watanabe, Fumitaka Suzuki, et al.Pageof 5